Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Jubilant Pharmova has informed that it enclosed a communication pertaining to investment of $92 million by Jubilant Pharma, a wholly-owned subsidiary of the Company for expansion of sterile injectable manufacturing capacity at the Spokane site in Washington, US.
The above information is a part of company’s filings submitted to BSE.